A proteomic approach to obesity and type 2 diabetes |
| |
| Authors: | Elena López‐Villar Gabriel Á. Martos‐Moreno Julie A. Chowen Shigeru Okada John J. Kopchick Jesús Argente |
| |
| Affiliation: | 1. Departments of Endocrinology and Pediatrics, Hospital Infantil Universitario Ni?o Jesús, Universidad Autónoma de Madrid, Madrid, Spain;2. Oncohematology and Pediatrics, Hospital Infantil Universitario Ni?o Jesús, Madrid, Spain;3. Instituto de Investigación La Princesa, Madrid, Spain;4. Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain;5. Edison Biotechnology Institute, Ohio University, Konneker Research Laboratories, Athens, OH, USA;6. Department of Pediatrics, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA;7. Molecular and Cellular Biology Program, Ohio University, Athens, OH, USA;8. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA |
| |
| Abstract: | The incidence of obesity and type diabetes 2 has increased dramatically resulting in an increased interest in its biomedical relevance. However, the mechanisms that trigger the development of diabetes type 2 in obese patients remain largely unknown. Scientific, clinical and pharmaceutical communities are dedicating vast resources to unravel this issue by applying different omics tools. During the last decade, the advances in proteomic approaches and the Human Proteome Organization have opened and are opening a new door that may be helpful in the identification of patients at risk and to improve current therapies. Here, we briefly review some of the advances in our understanding of type 2 diabetes that have occurred through the application of proteomics. We also review, in detail, the current improvements in proteomic methodologies and new strategies that could be employed to further advance our understanding of this pathology. By applying these new proteomic advances, novel therapeutic and/or diagnostic protein targets will be discovered in the obesity/Type 2 diabetes area. |
| |
| Keywords: | diabetes mellitus type 2 obesity proteomics biomarkers |
|
|
